Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2S1 | P05198 | 9/20 | 0.37 |
| ▸ | EIF2AK3 | Q9NZJ5 | 9/20 | 0.37 |
| ▸ | FAAH | O00519 | 2/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.34 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.34 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL880173 | 1.00 | EIF2S1 (0.37) | EIF2S1EIF2AK3FAAHPSEN1PSEN2 | |
| SCHEMBL6520061 | 0.88 | EIF2S1 (0.39) | EIF2S1EIF2AK3 | |
| SCHEMBL6518890 | 0.87 | MAPT (0.43) | KMT2A | |
| SCHEMBL6518886 | 0.87 | MAPT (0.43) | KMT2A | |
| SCHEMBL880178 | 0.87 | MAPT (0.43) | KMT2A | |
| SCHEMBL880168 | 0.82 | EIF2AK3 (0.37) | EIF2S1EIF2AK3PSEN1PSEN2APH1B | |
| SCHEMBL6518734 | 0.82 | EIF2AK3 (0.37) | EIF2S1EIF2AK3PSEN1PSEN2APH1B | |
| SCHEMBL880175 | 0.82 | EIF2AK3 (0.37) | EIF2S1EIF2AK3PSEN1PSEN2APH1B | |
| SCHEMBL12310656 | 0.75 | CNR1 (0.40) | MEN1KMT2A | |
| SCHEMBL12310836 | 0.73 | HDAC3 (0.39) | PPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546613-B2 | SGK1 inhibitors for the prophylaxis and/or therapy of viral diseases and/or carcinomas | MERCK PATENT GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| EP-2242738-B1 | SGK1 INHIBITORS FOR THE PROPHYLAXIS AND/OR THERAPY OF VIRAL DISEASES AND/OR CARCINOMAS | MERCK PATENT GMBH (DE) | 2012-03-28 | — | — | EP | disclosed |
| US-20110060050-A1 | SGK1 INHIBITORS FOR THE PROPHYLAXIS AND/OR THERAPY OF VIRAL DISEASES AND/OR CARCINOMAS | MERCK PATENT GMBH (DE) | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110060050-A1 | SGK1 INHIBITORS FOR THE PROPHYLAXIS AND/OR THERAPY OF VIRAL DISEASES AND/OR CARCINOMAS | NCOA1, NR3C2, NCOA2 | EIF2S1 927/4885EIF2AK3 453/4885FAAH 4584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.